First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis.

BACKGROUND The increased prevalence of diabetes in schizophrenia is partly attributed to antipsychotic treatment, in particular second-generation antipsychotics, but the evidence has not been systematically reviewed. AIMS Systematic review and meta-analysis comparing diabetes risk for different antipsychotics in people with schizophrenia. METHOD We searched MEDLINE, PsycINFO, EMBASE, International Pharmaceutical Abstracts, CINAHL and Web of Knowledge until September 2006. Studies were eligible for inclusion if the design was cross-sectional, case-control, cohort or a controlled trial in individuals with schizophrenia or related psychotic disorders, where second-generation antipsychotics (defined as clozapine, olanzapine, risperidone and quetiapine) were compared with first-generation antipsychotics and diabetes was an outcome. Data were pooled using random effects inverse variance weighted meta-analysis. RESULTS Of the studies that met the inclusion criteria (n=14), 11 had sufficient data to include in the meta-analysis. Four of these were retrospective cohort studies. The relative risk of diabetes in patients with schizophrenia prescribed one of the second-generation v. first-generation antipsychotics was 1.32 (95% CI 1.15-1.51). There were insufficient data to include aripiprazole, ziprasidone and amisulpride in this analysis. CONCLUSIONS There is tentative evidence that the second-generation antipsychotics included in this study are associated with a small increased risk for diabetes compared with first-generation antipsychotics in people with schizophrenia. Methodological limitations were found in most studies, leading to heterogeneity and difficulty interpreting data. Regardless of type of antipsychotic, screening for diabetes in all people with schizophrenia should be routine.

[1]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.

[2]  Donald R. Miller,et al.  Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. , 2006, American journal of epidemiology.

[3]  R. Holt,et al.  Antipsychotic drugs and diabetes—an application of the Austin Bradford Hill criteria , 2006, Diabetologia.

[4]  D. Cohen,et al.  Prevalence of diabetes mellitus in chronic schizophrenic inpatients in relation to long-term antipsychotic treatment , 2006, European Neuropsychopharmacology.

[5]  E. Tafesse,et al.  Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case‐control study of California Medicaid claims , 2005, Pharmacoepidemiology and drug safety.

[6]  Ronald R. Brown,et al.  Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine , 2005, International clinical psychopharmacology.

[7]  A. Young,et al.  Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study , 2005, Diabetologia.

[8]  M. Miller,et al.  Prevalence of diabetes mellitus in patients receiving depot neuroleptics or clozapine. , 2005, Archives of psychiatric nursing.

[9]  G. Mazzaglia,et al.  Incidence of diabetes in a general practice population: a database cohort study on the relationship with haloperidol, olanzapine, risperidone or quetiapine exposure , 2005, International clinical psychopharmacology.

[10]  J. Levine,et al.  Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. , 2004, Psychiatric services.

[11]  R. Rosenheck,et al.  Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. , 2004, The American journal of psychiatry.

[12]  J. Ananth,et al.  Side effects of atypical antipsychotic drugs. , 2004, Current pharmaceutical design.

[13]  C. Byrne,et al.  Schizophrenia, the metabolic syndrome and diabetes , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[14]  S. Wild,et al.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.

[15]  D. Ollendorf,et al.  Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. , 2004, MedGenMed : Medscape general medicine.

[16]  P. Rochon,et al.  Exploring the Association Between Atypical Neuroleptic Agents and Diabetes Mellitus in Older Adults , 2003, Pharmacotherapy.

[17]  S. Madhusoodanan,et al.  Hyperglycemia and Hypertriglyceridemia in Real World Patients on Antipsychotic Therapy , 2003, American journal of therapeutics.

[18]  H. Nasrallah,et al.  Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. , 2003 .

[19]  K. Melkersson,et al.  Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses , 2003, Psychopharmacology.

[20]  S. Chong,et al.  Diabetes Mellitus and Impaired Glucose Tolerance in Patients with Schizophrenia , 2003, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[21]  D. Umbricht,et al.  Atypical antipsychotics in the treatment of schizophrenia. , 2003, Swiss medical weekly.

[22]  J. Lieberman,et al.  Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. , 2003, The American journal of psychiatry.

[23]  J. Caro,et al.  The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. , 2002, The Journal of clinical psychiatry.

[24]  H. Nasrallah,et al.  Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. , 2002, The Journal of clinical psychiatry.

[25]  J. Ananth,et al.  Atypical Antipsychotic Drug Use and Diabetes , 2002, Psychotherapy and Psychosomatics.

[26]  Julie Kreyenbuhl,et al.  Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study , 2002, BMJ : British Medical Journal.

[27]  W. Regenold,et al.  Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. , 2002, Journal of affective disorders.

[28]  Jonathan M. Meyer.  A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. , 2002, The Journal of clinical psychiatry.

[29]  Z. Zhao,et al.  PMH6 RISK OF DIABETES FOR INDIVIDUALS WITH SCHIZOPHRENIA TREATED WITH ANTIPSYCHOTICS , 2002 .

[30]  Robert Rosenheck,et al.  Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. , 2002, The American journal of psychiatry.

[31]  D. Jeste,et al.  Phenomenology of and Risk Factors for New-Onset Diabetes Mellitus and Diabetic Ketoacidosis Associated with Atypical Antipsychotics: An Analysis of 45 Published Cases , 2002 .

[32]  Stephan Arndt,et al.  Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. , 2001, Archives of general psychiatry.

[33]  Douglas G Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[34]  B. Kang,et al.  The effect of clozapine on blood glucose metabolism , 2001, Human psychopharmacology.

[35]  I. Olkin,et al.  Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .

[36]  Mark Woodward,et al.  Epidemiology: Study Design and Data Analysis , 1999 .

[37]  P. Raskin,et al.  Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.

[38]  O. Spigset,et al.  Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. , 1998, The Journal of clinical psychiatry.

[39]  A. Amos,et al.  The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010 , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[40]  A R Jadad,et al.  Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. , 1995, Controlled clinical trials.

[41]  A. B. Prasad,et al.  British National Formulary , 1994 .

[42]  M. First,et al.  The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. , 1992, Archives of general psychiatry.

[43]  A. B. Hill.  The Environment and Disease: Association or Causation? , 1965, Proceedings of the Royal Society of Medicine.

[44]  Simon Davies,et al.  Epidemiology: Study Design and Data Analysis (2nd ed.) , 2006 .

[45]  N. Sicolo,et al.  Effect of chlorpromazine on blood glucose and plasma insulin in man , 2004, European Journal of Clinical Pharmacology.

[46]  A. Colotto,et al.  Antipsicotici e implicazioni metaboliche: Valutazione sulla casistica dell'U.O. di Psichiatria di Aosta , 2003 .

[47]  D. Henderson.  Atypical Antipsychotic-Induced Diabetes Mellitus , 2002, CNS drugs.

[48]  E. Oral,et al.  Comparison of the effects of classical and novel antipsychotic drugs on the insulin and glucose metabolisms of patients with schizophrenia and other psychotic disorders , 2002 .

[49]  Douglas G. Altman,et al.  Systematic Reviews in Health Care , 2001 .

[50]  L. Dixon,et al.  Prevalence and correlates of diabetes in national schizophrenia samples. , 2000, Schizophrenia bulletin.

[51]  P. Decina,et al.  Diabetes mellitus in schizophrenic patients. , 1996, Comprehensive psychiatry.